市場調査レポート
商品コード
1268946
精密医療ソフトウェアの世界市場-2023-2030Global Precision Medicine Software Market - 2023-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
精密医療ソフトウェアの世界市場-2023-2030 |
出版日: 2023年05月02日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
|
精密医療ソフトウェア市場は、2022年に記録した15億5,070万米ドルから、2030年には37億640万米ドルに達し、予測期間中に11.8%のCAGRで成長すると予測されます。主な市場プレイヤーが、製品発表、買収、提携、共同研究、事業拡大などのさまざまな市場戦略を通じて、市場シェアの大半を占めています。
例えば、2023年03月01日、フィリップスは、腫瘍学、病理学、放射線学、循環器学のクルーをつなぎ、臨床的な確信を高め、診断と治療の精度を促進するための完全相互運用性のスマート画像システムおよび情報学ソリューションを発表しました。例えば、2023年1月9日、がんの分子プロファイリングのリーダーであるFoundation Medical, Inc.と無細胞DNA検査の世界的リーダーであるNatera, Inc.によって、臨床利用のための早期アクセスプログラムの一環として、個人向け循環腫瘍DNA(ctDNA)モニタリングアッセイFoundationOne Trackerが考案されました。さらに、臨床試験では、本検査の治験薬使用のみのバリアントを採用できるようになりました。
世界の精密医療ソフトウェア市場は、ゲノミクスの進歩、電子健康記録(EHR)の導入拡大、個別化医療への需要の高まりなどを背景に、近年著しい成長を遂げています。精密医療が主流となり、日常的な臨床診療に組み込まれるようになるにつれ、市場は今後数年間、かなりの速度で成長し続けると予想されます。
DNA配列決定技術などゲノミクスの急速な進歩により、膨大な量のゲノムデータが生成されるようになりました。精密医療ソフトウェアは、このゲノムデータを分析・解釈し、病気の原因となる遺伝子変異の特定、治療方針の決定、個別化された治療計画の策定において重要な役割を担っています。
電子健康記録(EHR)の普及は、精密医療分野を含むヘルスケア産業の大きな推進力となっています。EHRは、病状、診断、治療、投薬、その他の関連する健康情報など、患者の病歴をデジタル化したもので、電子形式で保存され、権限を持つ医療従事者がアクセスすることができます。
EHRの導入は、政府の取り組み、規制要件、技術の進歩、ヘルスケア成果の向上の必要性など、さまざまな要因によって推進されてきました。EHRは、ヘルスケアプロバイダーに、精密医療に不可欠なゲノムデータを含む、患者の包括的な病歴への迅速かつ容易なアクセスを提供します。これにより、ヘルスケアプロバイダーは、患者さんのケアについてより多くの情報に基づいた意思決定を行い、個人に合わせた治療計画を立て、個人の健康上の特徴に基づいた介入を行うことができます。
EHRは、異なるヘルスケアプロバイダーや施設間で患者情報をシームレスに交換することができ、より良いケアの連携を促進します。これは、遺伝学者、腫瘍学者、薬剤師、その他の専門家を含む複数の利害関係者が患者のケアに関与する可能性がある精密医療において、特に重要です。EHRは、ゲノムデータ、臨床データ、その他の関連情報の交換を可能にし、異なるヘルスケア環境における精密医療の意思決定をサポートします。
精密医療ソフトウェアのコストが高いことは、世界の精密医療ソフトウェア市場の成長に影響を与える可能性のある重大な市場抑制要因の1つです。精密医療ソフトウェアは、ゲノムデータ、臨床データ、ライフスタイルデータなどの大量のデータを分析・解釈し、患者にパーソナライズされた治療計画を提供するための複雑なアルゴリズムとデータ分析を伴います。このような高度なソフトウェアソリューションのアプリケーションタイプ、実装、メンテナンスにはコストがかかるため、導入と活用に課題をもたらす可能性があります。
精密医療ソフトウェアは、ゲノムデータ解析、データ統合、意思決定アルゴリズムにおける最新の進歩に対応するための継続的な研究が必要です。精密医療ソフトウェアの開発・更新のための研究開発への投資は、特にリソースの限られた中小企業や組織にとっては、コストがかかる可能性があります。
COVID-19の流行は、遠隔医療、遠隔モニタリング、デジタルヘルスソリューションの利用など、ヘルスケアにおけるデジタル技術の採用を加速させています。このようなデジタル技術への依存の高まりは、ゲノムデータへの遠隔アクセス、遠隔診療の促進、遠隔モニタリングや患者の個別化治療計画を可能にする精密医療ソフトウェアの採用も促進する可能性があります。精密医療ソフトウェアは、COVID-19に対する潜在的な治療法やワクチンの臨床試験の管理も支援することができます。
COVID-19の大流行は、精密医療を含む多くの分野の研究を混乱させました。臨床試験、データ収集、研究協力は、ロックダウン、渡航制限、パンデミックに対処するための資源再配分によって影響を受けています。
精密医療は、分析および意思決定のために大規模かつ多様なデータセットの利用可能性に大きく依存しています。紛争は、ロシアとウクライナ間のデータ共有と交換を混乱させ、精密医療の研究と応用のための関連患者データへのアクセスを制限することにつながる可能性があります。紛争は、研究者や臨床医を含むヘルスケア専門家の被災地からの転居につながる可能性があります。その結果、精密医療分野の専門知識や人材が失われ、研究努力が挫折する可能性があります。状況は複雑で進化しており、精密医療ソフトウェアへの実際の影響は、紛争の具体的な状況によって異なる可能性があることに留意することが重要です。
The precision medicine software market is expected to reach US$ 3,706.4 million in 2030, from its recorded value of US$ 1,550.7 million in 2022, growing with a CAGR of 11.8% during the forecast period. A few of the key market players such as Hitachi Vantara LLC (Hitachi, Ltd.), Koninklijke Philips N.V., Syapse, Inc., SOPHiA GENETICS, QIAGEN, Velsera, Foundation Medicine Inc. (F. Hoffmann-La Roche Ltd), 2bPrecise (AccessDx Laboratory), Pieriandx, Inc., MediCardia Health, Translational Software Inc., and Lifeomic Holdings LLC among others hold a majority of the market share through various market strategies such as product launches, acquisitions, partnerships, collaborations, and business expansions.
For instance, on March 01, 2023, Philips introduced its completely interoperable smart imaging systems and informatics solutions to connect crews in oncology, pathology, radiology, and cardiology to improve clinical conviction and promote precision in diagnosis and treatment. For instance, on January 09, 2023, the personalized circulating tumor DNA (ctDNA) monitoring assay FoundationOne Tracker was invented by Foundation Medical, Inc., a leader in molecular profiling for cancer, and Natera, Inc., a world leader in cell-free DNA testing, as part of an early access program for clinical usage. Moreover, clinical trials can now employ the test's investigational use-only variant.
The global precision medicine software market has been witnessing significant growth in recent years, driven by advancements in genomics, increasing adoption of electronic health records (EHRs), and growing demand for personalized medicine. The market is expected to continue to grow at a considerable rate in the coming years, as precision medicine becomes more mainstream and integrated into routine clinical practice.
Rapid advancements in genomics, including DNA sequencing technologies, have enabled the generation of vast amounts of genomic data. Precision medicine software plays a critical role in analyzing and interpreting this genomic data to identify disease-causing genetic mutations, guide treatment decisions, and develop personalized treatment plans.
The increasing adoption of electronic health records (EHRs) has been a significant driver in the healthcare industry, including the field of precision medicine. EHRs are digital versions of a patient's medical history, including their medical conditions, diagnoses, treatments, medications, and other relevant health information, which are stored in electronic format and can be accessed by authorized healthcare providers.
The adoption of EHRs has been driven by various factors, including government initiatives, regulatory requirements, technological advancements, and the need for improved healthcare outcomes. EHRs provide healthcare providers with quick and easy access to a patient's comprehensive medical history, including genomic data, which is crucial for precision medicine. This enables healthcare providers to make more informed decisions about patient care, develop personalized treatment plans, and tailor interventions based on an individual's unique health characteristics.
EHRs allow for a seamless exchange of patient information among different healthcare providers and facilities, facilitating better coordination of care. This is especially important in precision medicine, where multiple stakeholders, including geneticists, oncologists, pharmacists, and other specialists, may be involved in a patient's care. EHRs enable the exchange of genomic data, clinical data, and other relevant information, supporting precision medicine decision-making across different healthcare settings.
The high cost of precision medicine software is one of the significant market restraints that may impact the global precision medicine software market growth. Precision medicine software involves complex algorithms and data analytics to analyze and interpret large amounts of data, including genomic data, clinical data, and lifestyle data, to provide personalized treatment plans for patients. The application type, implementation, and maintenance of such sophisticated software solutions can be costly, which may pose challenges for adoption and utilization.
Precision medicine software requires continuous research to keep up with the latest advancements in genomic data analysis, data integration, and decision-making algorithms. Investing in R&D to develop and update precision medicine software can be costly, especially for smaller companies or organizations with limited resources.
The COVID-19 pandemic has accelerated the adoption of digital technologies in healthcare, including the use of telemedicine, remote monitoring, and digital health solutions. This increased reliance on digital health technologies may also drive the adoption of precision medicine software, which can provide remote access to genomic data, facilitate teleconsultations, and enable remote monitoring and personalized treatment plans for patients. Precision medicine software can also aid in the management of clinical trials for potential treatments and vaccines for COVID-19.
The COVID-19 pandemic has disrupted research in many areas, including precision medicine. Clinical trials, data collection, and research collaborations have been impacted by lockdowns, travel restrictions, and resource reallocation to address the pandemic.
Precision medicine relies heavily on the availability of large and diverse datasets for analysis and decision-making. The conflict may disrupt data sharing and exchange between Russia and Ukraine, leading to limited access to relevant patient data for precision medicine research and applications. Conflict can lead to the displacement of healthcare professionals, including researchers and clinicians, from the affected region. This can result in a loss of expertise and talent in the field of precision medicine, leading to potential setbacks in research efforts. It's important to note that the situation is complex and evolving, and the actual impact on precision medicine software may vary depending on the specific circumstances of the conflict.
The global precision medicine software market is segmented based on delivery mode, application type, end user, and region.
The market value for cloud-based segment is likely to reach US$ 2,436.6 million in 2030, from its recorded value of US$ 1,011.8 million in 2022, growing with a CAGR of 11.9% during the forecast period (2023 to 2030).
Cloud-based deployment means renting an internet space from a third party and storing the data on remote servers. This solution is convenient as it has no upfront costs and requires no additional staff to maintain hardware. Cloud deployment is scalable and flexible according to the budget and usage, eases the burden on IT staff, and easier to perform regular backups.
For instance, Synapse Raydar is a complete real-world data platform created by combining technology, deep clinical understanding, regulatory experience, and rigorous quality control. Raydar converts clinically complicated, highly contextual oncology data into actionable insights.
Raydar's patented capabilities illuminate the entire patient journey via Raydar Interoperability, Raydar Knowledge Management Services, Raydar AI, and Raydar Algo. Similarly, 2bPrecise technology, which is cloud-based, absorbs molecular data from laboratories and clinical information from EHRs, synthesizing them into a clinical-genomic ontology and giving precision medicine insights to doctors inside their familiar workflow across any EHR. Furthermore, the solution is designed to interact with changing information sources and care recommendations. When combined with the rest of the patient information, this actionable data set contributes to improved diagnosis and early treatment.
The North American precision medicine software market was valued at US$ 667.2 million in 2022 and is likely to reach US$ 1,611.3 million by 2030, growing at a CAGR of 12.0% during 2023-2030.
North America accounted for the highest market share of 43.0% in 2022, which will increase to 43.37% in 2030. The presence of a large number of pharmaceutical companies, growing R&D expenditure, rising patient preference for precision medicine, collaborative agreements among manufacturers, and surging cancer patients, new product launches, and technological advancements are driving the growth of the market in the region.
For instance, according to National Cancer Institute, approximately 1,806,590 new cases were analyzed with cancer, which led to 606,520 deaths in 2020. Moreover, the American Cancer Society identified 1.9 million cancer cases in 2021, and over 608,570 deaths were cancer-related. Similarly, CDC assessed that annual new cancer cases will be 29.5 million by 2040.
Moreover, the presence of key market players such as Syapse, Inc, 2bprecise, LLC, Fabric Genomics, Inc., Foundation Medicine, Inc., Velsera, Translational Software Inc., LifeOmic Holdings LLC, and Koninklijke Philips N.V. among others holding most of the precision medicine software market is expected to ensure the growth of North American precision medicine software market at a high CAGR throughout the forecast period.
The precision medicine software market is highly competitive with the presence of a large number of existing major players and small vendors. Some of the major players in the global precision medicine software market include Hitachi Vantara LLC (Hitachi, Ltd.), Koninklijke Philips N.V., Syapse, Inc., SOPHiA GENETICS, QIAGEN, Velsera, Foundation Medicine Inc. (F. Hoffmann-La Roche Ltd), 2bPrecise (AccessDx Laboratory), Pieriandx, Inc., MediCardia Health, Translational Software Inc., and Lifeomic Holdings LLC among others.
The global precision medicine software market report would provide approximately 54 tables, 46 figures, and 195 Pages.
LIST NOT EXHAUSTIVE